Program iii. · Weight Care
The Weight
Program.
Medically supervised weight management with FDA-approved, brand-name GLP-1 medications only. Comprehensive monitoring. Continuous physician oversight. The discipline to say no to shortcuts.
Important · Brand-name only
As of 2025, California has imposed significant restrictions on compounded semaglutide and tirzepatide. We prescribe only Wegovy®, Ozempic®, Zepbound®, and Mounjaro®, dispensed through a licensed pharmacy. This is a deliberate clinical and legal choice.
i. What's included
The program.
- Good Faith Examination and enrollment
- Baseline labs and clinical assessment
- Brand-name GLP-1 prescription
- Dose titration under physician supervision
- Monthly clinical check-ins
- Adverse event monitoring
ii. Safety first
Who should not enroll.
- Personal or family history of medullary thyroid carcinoma or MEN 2
- Current or prior pancreatitis
- Active pregnancy or planned within 60 days
- Active severe gastroparesis
- Active eating disorder
Frequently Asked
About the Program.
California imposed significant restrictions on compounded semaglutide and tirzepatide in 2025. We believe FDA-approved, brand-name medications offer the most reliable safety profile.
Some plans cover GLP-1 medications for specific diagnoses. Our staff can help with prior authorization. Medication is billed separately by the pharmacy.
Results vary. Clinical trial data for Wegovy and Zepbound show average weight loss of 15–22% over 68–72 weeks combined with lifestyle modification.
GLP-1 therapy is typically long-term, analogous to other chronic-condition medications. Your physician will discuss a personalized course during your initial visits.
Ready to discuss the program?
Schedule a Consultation →